RecruitingPhase NA

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

A Prospective Clinical Study to Investigate Dopamine Level Changes in the Brain at Food Cognition by GLP-1 Receptor Agonists

Lead sponsor

Seoul National University Hospital

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07732426

Org study ID2501-006-1602

Timeline

Milestones

Study start2026-07-15actual

Study first posted2026-07-28actual

Last update posted2026-07-28actual

Primary completion2028-02-29estimated

Study completion2028-06-30estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age19 Years

Maximum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Participants aged between 19 and 50 years.

•Eligible for treatment with semaglutide, defined as either:

•Initial body mass index (BMI) of 30 kg/m2 or higher; or

•Initial BMI of 27 kg/m2 to less than 30 kg/m2 with at least one weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

•Mild or greater food addiction tendency, defined as a Yale Food Addiction Scale (YFAS) score of 3 or higher.

•Able to understand the study tasks and provide appropriate responses.

Exclusion criteria

•Use of medications that may affect body weight or dopaminergic medications within the past 2 months.

•Known hypersensitivity to semaglutide.

•Pregnant, breastfeeding, or planning to become pregnant.

•Severe renal impairment, hepatic impairment, heart failure, acute pancreatitis, or thyroid disease.

•Any medical condition, disease, or medical history that, in the investigator's judgment, would make it difficult for the participant to complete the study or would interfere with interpretation of the study results.

•Allergy to ingredients in chocolate milk, including milk or soy, or to ingredients that may be present through cross-contamination, including egg, buckwheat, peanut, wheat, peach, tomato, walnut, pork, or beef.

•Participants with both no self-reported preference for chocolate milk and a chocolate milk preference score of less than 5 on a 10-point visual analog scale (VAS).

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.